Lapse or Relapse to Drug Abuse and Other Chronic Conditions

The summary for the Lapse or Relapse to Drug Abuse and Other Chronic Conditions grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Lapse or Relapse to Drug Abuse and Other Chronic Conditions: The National Institute on Drug Abuse (NIDA) invites applications in which a behavioral, cognitive, social cognitive or neurobiological approach is used to advance our understanding of the causes, consequences and treatment of drug abuse relapse. The purpose of this RFA is to stimulate research that will lead to an improved understanding of the relapsing nature of drug addiction. This RFA particularly encourages interdisciplinary research that fosters collaboration between basic and applied researchers, between those studying humans in laboratory settings and those studying clinical populations. In addition, researchers who study other chronic, relapsing conditions (e.g., obesity, depression, anxiety disorders) are encouraged to apply their research approaches or paradigms to the problem of drug abuse and addiction. To the extent that relapse is a common feature of many chronic diseases, an understanding of drug abuse relapse will have considerable gene! ralizability beyond the phenomenon of drug addiction.

Federal Grant Title:	Lapse or Relapse to Drug Abuse and Other Chronic Conditions
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-05-004
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Jan 18, 2005
Posted Date:	Nov 09, 2004
Creation Date:	Nov 09, 2004
Archive Date:	Feb 17, 2005
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	6
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Public and State controlled institutions of higher education Private institutions of higher education State governments County governments City or township governments Special district governments Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed); • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required); • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...; • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...